Facts of CAPRELSA (vandetanib) tablets 300mg ?
- Medicine Name: CAPRELSA
- Generic Name: Vandetanib
- Approval Date: Feb 21, 2012
- Company Name: AstraZeneca Pharmaceuticals LP
- Available as (Form & Strength): 100 mg and 300mg tablets
What are the indications and usage?
- CAPRELSA is a kinase inhibitor indicated for the treatment of symptomatic or progressive medullary thyroid cancer in patients with unresectable locally advanced or metastatic disease.
- Use CAPRELSA in patients with indolent, asymptomatic or slowly progressing disease only after careful consideration of the treatment related risks of CAPRELSA.